tamsulosin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	2562	106133-20-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tamsulosin tamsulosin hydrochloride tamsulosin HCl LY-253352	A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA. Molecular weight: 408.51 Formula: C20H28N2O5S CLOGP: 2.17 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 99.88 ALOGS: -4.79 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tamsulosin
tamsulosin hydrochloride
tamsulosin HCl
LY-253352

A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA.

Molecular weight: 408.51
Formula: C20H28N2O5S
CLOGP: 2.17
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 99.88
ALOGS: -4.79
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	8.70 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.03 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.62 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 15, 1997	FDA	BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrolithiasis	174.85	15.42	91	7485	36656	53304834
Urinary tract infection	84.24	15.42	134	7442	239769	53101721
Multiple sclerosis relapse	74.46	15.42	57	7519	44796	53296694
Urinary retention	58.12	15.42	41	7535	28425	53313065
Residual urine volume increased	44.61	15.42	7	7569	24	53341466
Ligament pain	32.24	15.42	7	7569	175	53341315
Rheumatoid arthritis	31.12	15.42	4	7572	314527	53026963
Renal colic	29.91	15.42	10	7566	1317	53340173
Respiratory tract inflammation	28.65	15.42	8	7568	575	53340915
Drug ineffective	25.99	15.42	48	7528	817197	52524293
Progressive multifocal leukoencephalopathy	25.98	15.42	18	7558	12111	53329379
Disorganised speech	23.96	15.42	8	7568	1049	53340441
Pertussis	23.77	15.42	7	7569	609	53340881
Multiple sclerosis	23.77	15.42	24	7552	27129	53314361
Renal stone removal	22.88	15.42	5	7571	129	53341361
Urinary tract obstruction	22.84	15.42	9	7567	1892	53339598
Chorioretinitis	22.14	15.42	6	7570	386	53341104
Sinus pain	21.18	15.42	9	7567	2290	53339200
Hydronephrosis	20.53	15.42	14	7562	9182	53332308
Immune reconstitution inflammatory syndrome	19.98	15.42	12	7564	6334	53335156
Flank pain	19.37	15.42	16	7560	13980	53327510
Iris disorder	19.04	15.42	4	7572	85	53341405
Product use issue	18.04	15.42	52	7524	139532	53201958
Hypertensive nephropathy	16.66	15.42	5	7571	464	53341026
Central nervous system stimulation	16.21	15.42	3	7573	32	53341458
Erythropenia	15.72	15.42	4	7572	201	53341289
Product use in unapproved indication	15.65	15.42	43	7533	112246	53229244

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Iris disorder	742.82	10.73	201	165432	163	32347730
Urinary retention	403.43	10.73	683	164950	35014	32312879
Dizziness	362.40	10.73	2057	163576	207561	32140332
Fall	344.77	10.73	1934	163699	194267	32153626
Orthostatic hypotension	283.43	10.73	486	165147	25164	32322729
Cataract operation complication	256.41	10.73	73	165560	86	32347807
Syncope	255.89	10.73	1022	164611	89102	32258791
Iridocele	224.50	10.73	58	165575	30	32347863
Drug abuse	215.60	10.73	70	165563	80173	32267720
Urinary tract infection	205.20	10.73	880	164753	79191	32268702
Dysuria	180.70	10.73	396	165237	24614	32323279
Floppy iris syndrome	177.73	10.73	66	165567	265	32347628
Toxicity to various agents	173.81	10.73	408	165225	177633	32170260
Procedural complication	160.37	10.73	156	165477	4544	32343349
Benign prostatic hyperplasia	146.82	10.73	242	165391	12122	32335771
Pollakiuria	140.20	10.73	301	165332	18443	32329450
Idiopathic pulmonary fibrosis	119.33	10.73	129	165504	4266	32343627
Completed suicide	111.69	10.73	187	165446	92330	32255563
Product prescribing error	108.62	10.73	281	165352	19436	32328457
Off label use	105.12	10.73	1026	164607	305294	32042599
Drug ineffective	99.18	10.73	1368	164265	382109	31965784
Urinary incontinence	96.74	10.73	256	165377	17951	32329942
Haematuria	95.54	10.73	493	165140	47868	32300025
Micturition urgency	93.54	10.73	126	165507	5260	32342633
Nocturia	93.43	10.73	169	165464	9125	32338768
Retrograde ejaculation	92.25	10.73	42	165591	310	32347583
Asthenia	91.71	10.73	1699	163934	234245	32113648
Multiple organ dysfunction syndrome	91.13	10.73	134	165499	69720	32278173
Prostatomegaly	85.03	10.73	116	165517	4902	32342991
Fatigue	80.61	10.73	2346	163287	348355	31999538
Drug resistance	80.02	10.73	11	165622	22954	32324939
Atrial fibrillation	78.74	10.73	925	164708	115779	32232114
Febrile neutropenia	72.86	10.73	337	165296	119229	32228664
Urine flow decreased	72.16	10.73	56	165577	1193	32346700
Prostate cancer	69.16	10.73	300	165333	27106	32320787
Presyncope	68.52	10.73	219	165414	17082	32330811
Intentional overdose	67.84	10.73	67	165566	41534	32306359
Pupillary disorder	67.58	10.73	32	165601	261	32347632
Product monitoring error	67.18	10.73	74	165559	2500	32345393
Hypotension	65.69	10.73	1501	164132	214609	32133284
Prostatic disorder	65.11	10.73	80	165553	3044	32344849
Hallucination	62.10	10.73	470	165163	52149	32295744
Cytomegalovirus infection	61.96	10.73	26	165607	25438	32322455
Drug dependence	60.41	10.73	22	165611	23462	32324431
Confusional state	58.78	10.73	1040	164593	142075	32205818
Treatment failure	58.37	10.73	68	165565	39095	32308798
Prostatic specific antigen increased	56.92	10.73	172	165461	13015	32334878
Balance disorder	56.24	10.73	369	165264	39090	32308803
Abdominal pain lower	52.82	10.73	136	165497	9377	32338516
Urogenital haemorrhage	52.54	10.73	33	165600	493	32347400
Miosis	52.06	10.73	128	165505	8576	32339317
Cardio-respiratory arrest	48.57	10.73	136	165497	55853	32292040
Suicide attempt	47.32	10.73	76	165557	38168	32309725
Labelled drug-drug interaction medication error	47.23	10.73	155	165478	12258	32335635
General physical health deterioration	46.73	10.73	836	164797	114423	32233470
Product substitution issue	45.87	10.73	137	165496	10299	32337594
Drug reaction with eosinophilia and systemic symptoms	45.67	10.73	59	165574	32426	32315467
Pyrexia	45.49	10.73	1262	164371	318706	32029187
Respiratory arrest	45.49	10.73	48	165585	28860	32319033
Bradycardia	43.35	10.73	556	165077	71006	32276887
Alanine aminotransferase increased	43.28	10.73	229	165404	78250	32269643
Dyspnoea	42.97	10.73	2254	163379	359791	31988102
Memory impairment	41.97	10.73	351	165282	40128	32307765
Leukopenia	41.81	10.73	161	165472	59961	32287932
Ocular procedural complication	41.66	10.73	15	165618	54	32347839
Overdose	41.65	10.73	266	165367	86811	32261082
Ejaculation failure	40.96	10.73	34	165599	800	32347093
Bladder disorder	40.46	10.73	63	165570	3005	32344888
Gait disturbance	38.75	10.73	600	165033	79808	32268085
Cystitis	37.54	10.73	118	165515	9121	32338772
Peritonitis	37.52	10.73	35	165598	22295	32325598
Constipation	37.45	10.73	875	164758	125498	32222395
Bone marrow failure	37.07	10.73	61	165572	30343	32317550
Rheumatoid arthritis	36.59	10.73	111	165522	44433	32303460
Bladder spasm	36.04	10.73	33	165600	889	32347004
Thrombocytopenia	36.01	10.73	535	165098	147764	32200129
Haemophagocytic lymphohistiocytosis	35.98	10.73	7	165626	11328	32336565
Lower urinary tract symptoms	35.50	10.73	19	165614	206	32347687
Loss of consciousness	35.33	10.73	605	165028	82102	32265791
Cataract operation	35.22	10.73	37	165596	1183	32346710
Aspergillus infection	34.99	10.73	8	165625	11566	32336327
Nephrolithiasis	34.92	10.73	249	165384	27105	32320788
Cardiac arrest	34.36	10.73	321	165312	96455	32251438
Cataract	33.75	10.73	225	165408	23958	32323935
Bladder cancer	33.72	10.73	122	165511	10134	32337759
Peripheral swelling	33.70	10.73	512	165121	67833	32280060
Orbital myositis	33.64	10.73	16	165617	132	32347761
Neutropenia	33.11	10.73	517	165116	141658	32206235
Prostatitis	32.82	10.73	79	165554	5221	32342672
Muscular weakness	32.77	10.73	507	165126	67422	32280471
Disseminated intravascular coagulation	31.65	10.73	43	165590	23133	32324760
Hormone receptor positive breast cancer	31.64	10.73	10	165623	21	32347872
Graft versus host disease	31.63	10.73	8	165625	10798	32337095
Hepatic failure	31.43	10.73	86	165547	35594	32312299
Nipple pain	31.32	10.73	26	165607	612	32347281
Erectile dysfunction	31.03	10.73	190	165443	19649	32328244
Full blood count decreased	30.56	10.73	169	165464	16841	32331052
Vitreous loss	30.42	10.73	8	165625	5	32347888
Testicular swelling	29.90	10.73	37	165596	1418	32346475
Haematochezia	29.20	10.73	317	165316	38891	32309002
Hospice care	29.12	10.73	76	165557	5283	32342610
Plasmapheresis	29.03	10.73	20	165613	352	32347541
Contusion	28.94	10.73	279	165354	33189	32314704
Septic shock	28.45	10.73	220	165413	68769	32279124
Haematoma	28.39	10.73	226	165407	25458	32322435
Urinary tract obstruction	28.39	10.73	59	165574	3532	32344361
Priapism	28.38	10.73	72	165561	4919	32342974
Urosepsis	28.36	10.73	128	165505	11762	32336131
Dacryocystitis	28.29	10.73	8	165625	9	32347884
Vomiting	28.25	10.73	950	164683	234607	32113286
Product use in unapproved indication	28.13	10.73	296	165337	86908	32260985
Intentional product use issue	28.09	10.73	115	165518	42096	32305797
Oedema peripheral	27.62	10.73	769	164864	113322	32234571
Hypertonic bladder	27.59	10.73	35	165598	1376	32346517
Hepatic vein dilatation	27.00	10.73	16	165617	214	32347679
Intentional self-injury	26.82	10.73	19	165614	13881	32334012
Myelosuppression	26.72	10.73	13	165620	11663	32336230
Synovitis	26.64	10.73	11	165622	10867	32337026
Needle fatigue	26.34	10.73	20	165613	412	32347481
Head injury	26.27	10.73	167	165466	17496	32330397
Mucosal inflammation	26.27	10.73	85	165548	33349	32314544
Immune reconstitution inflammatory syndrome	26.25	10.73	8	165625	9551	32338342
Faeces discoloured	26.19	10.73	147	165486	14730	32333163
Dementia	26.09	10.73	136	165497	13250	32334643
Right atrial hypertrophy	25.97	10.73	18	165615	320	32347573
Drug intolerance	25.82	10.73	150	165483	50085	32297808
Pneumocystis jirovecii pneumonia	25.78	10.73	35	165598	18835	32329058
Coma	25.39	10.73	121	165512	42491	32305402
Atrial septal defect	25.35	10.73	3	165630	7022	32340871
Wound	25.13	10.73	133	165500	13034	32334859
Hot flush	24.57	10.73	150	165483	15496	32332397
Vertigo	24.33	10.73	209	165424	24074	32323819
Thrombotic microangiopathy	24.19	10.73	9	165624	9473	32338420
Bladder catheterisation	24.14	10.73	22	165611	589	32347304
Infusion related reaction	23.52	10.73	136	165497	45463	32302430
Hepatotoxicity	23.38	10.73	39	165594	19298	32328595
Hypoacusis	23.34	10.73	148	165485	15493	32332400
Drug hypersensitivity	23.32	10.73	250	165383	73150	32274743
Haematospermia	23.21	10.73	18	165615	383	32347510
Gait spastic	23.11	10.73	20	165613	499	32347394
Incontinence	22.99	10.73	72	165561	5554	32342339
Blood urine present	22.89	10.73	110	165523	10375	32337518
Aortic stenosis	22.74	10.73	60	165573	4198	32343695
Pathogen resistance	22.67	10.73	10	165623	9500	32338393
Myocardial infarction	22.63	10.73	478	165155	125198	32222695
Adverse drug reaction	22.56	10.73	216	165417	25645	32322248
Factitious disorder	22.20	10.73	9	165624	48	32347845
Prostatic mass	22.17	10.73	8	165625	29	32347864
Candida infection	22.12	10.73	32	165601	16771	32331122
Dizziness postural	22.05	10.73	73	165560	5799	32342094
Peritonitis bacterial	21.69	10.73	19	165614	12477	32335416
Micturition disorder	21.61	10.73	38	165595	2006	32345887
Platypnoea	21.57	10.73	8	165625	32	32347861
Urinary hesitation	21.56	10.73	41	165592	2300	32345593
Milk-alkali syndrome	21.50	10.73	20	165613	550	32347343
Dry mouth	21.31	10.73	202	165431	23917	32323976
Liver palpable	21.20	10.73	15	165618	276	32347617
Stress	21.19	10.73	57	165576	23725	32324168
Cornea verticillata	21.00	10.73	8	165625	35	32347858
Seizure	20.80	10.73	388	165245	103466	32244427
Poisoning	20.56	10.73	16	165617	11142	32336751
C-reactive protein increased	20.48	10.73	152	165481	47950	32299943
Palpitations	20.32	10.73	276	165357	35693	32312200
Ascites	20.12	10.73	121	165512	40070	32307823
Bladder neck obstruction	20.11	10.73	11	165622	125	32347768
Relapsing-remitting multiple sclerosis	20.02	10.73	20	165613	602	32347291
Acute respiratory distress syndrome	19.98	10.73	64	165569	25189	32322704
Brain oedema	19.85	10.73	22	165611	12938	32334955
Gait inability	19.80	10.73	172	165461	19875	32328018
Atrial enlargement	19.76	10.73	15	165618	309	32347584
Dysgeusia	19.74	10.73	208	165425	25323	32322570
Cytomegalovirus viraemia	19.65	10.73	5	165628	6722	32341171
Cytokine release syndrome	19.63	10.73	24	165609	13511	32334382
Pallor	19.41	10.73	190	165443	22691	32325202
Transaminases increased	19.40	10.73	64	165569	24964	32322929
Post micturition dribble	19.18	10.73	6	165627	12	32347881
Subdural haematoma	19.09	10.73	170	165463	19783	32328110
Pancreatitis	19.03	10.73	115	165518	38036	32309857
Iris atrophy	18.95	10.73	9	165624	74	32347819
Lacunar stroke	18.90	10.73	11	165622	142	32347751
Acute hepatic failure	18.80	10.73	23	165610	12946	32334947
Blood bilirubin increased	18.77	10.73	118	165515	38666	32309227
Idiopathic interstitial pneumonia	18.77	10.73	11	165622	144	32347749
Hepatitis C	18.54	10.73	25	165608	13493	32334400
Aortic valve stenosis	18.49	10.73	37	165596	2155	32345738
Aspartate aminotransferase increased	18.48	10.73	233	165400	66196	32281697
Perineal pain	18.24	10.73	22	165611	821	32347072
Agranulocytosis	18.22	10.73	60	165573	23417	32324476
Bronchopulmonary aspergillosis	18.08	10.73	26	165607	13661	32334232
Transient ischaemic attack	18.04	10.73	206	165427	25588	32322305
Hepatomegaly	18.03	10.73	16	165617	10441	32337452
Back pain	17.99	10.73	714	164919	110339	32237554
Periorbital haematoma	17.89	10.73	15	165618	358	32347535
Stomal hernia	17.81	10.73	10	165623	120	32347773
Bladder outlet obstruction	17.77	10.73	12	165621	204	32347689
Post transplant lymphoproliferative disorder	17.70	10.73	4	165629	5830	32342063
Iris haemorrhage	17.51	10.73	5	165628	6	32347887
Therapeutic product effect incomplete	17.43	10.73	131	165502	41210	32306683
Hepatitis	17.41	10.73	62	165571	23631	32324262
Intentional product misuse	17.29	10.73	110	165523	35941	32311952
Toxic epidermal necrolysis	17.13	10.73	51	165582	20542	32327351
Therapy non-responder	17.04	10.73	97	165536	32557	32315336
Congenital hiatus hernia	16.99	10.73	13	165620	271	32347622
Prostatism	16.91	10.73	13	165620	273	32347620
Herpes simplex	16.84	10.73	3	165630	5171	32342722
Tendon pain	16.67	10.73	41	165592	2747	32345146
Psoriatic arthropathy	16.53	10.73	42	165591	17818	32330075
Psychotic disorder	16.41	10.73	61	165572	22959	32324934
Bladder discomfort	16.40	10.73	9	165624	103	32347790
Prostatic obstruction	16.36	10.73	10	165623	142	32347751
Breast tenderness	16.36	10.73	20	165613	757	32347136
Haematotoxicity	16.35	10.73	7	165626	6769	32341124
Urinary tract disorder	16.35	10.73	34	165599	2036	32345857
Genital swelling	16.29	10.73	11	165622	187	32347706
Hip fracture	16.27	10.73	110	165523	11765	32336128
Product use issue	16.26	10.73	181	165452	52596	32295297
Guillain-Barre syndrome	16.24	10.73	63	165570	5411	32342482
Phaeochromocytoma malignant	16.22	10.73	8	165625	72	32347821
Prostatic operation	16.22	10.73	14	165619	348	32347545
Urinary bladder haemorrhage	16.15	10.73	31	165602	1751	32346142
Pancytopenia	16.12	10.73	348	165285	90887	32257006
Transurethral prostatectomy	16.06	10.73	14	165619	353	32347540
Hydronephrosis	16.04	10.73	93	165540	9430	32338463
Megakaryocytes increased	15.93	10.73	7	165626	47	32347846
Cardiogenic shock	15.90	10.73	53	165580	20609	32327284
Akathisia	15.80	10.73	8	165625	7017	32340876
Inferior vena cava dilatation	15.79	10.73	19	165614	707	32347186
Serum ferritin abnormal	15.77	10.73	12	165621	248	32347645
Dacryostenosis acquired	15.75	10.73	11	165622	198	32347695
Therapy partial responder	15.74	10.73	3	165630	4927	32342966
Status epilepticus	15.67	10.73	23	165610	11983	32335910
Resting tremor	15.56	10.73	18	165615	642	32347251
Tuberculosis	15.48	10.73	13	165620	8716	32339177
Nephropathy toxic	15.48	10.73	23	165610	11923	32335970
Intestinal haemorrhage	15.46	10.73	45	165588	3334	32344559
Ageusia	15.22	10.73	93	165540	9609	32338284
Drug ineffective for unapproved indication	15.09	10.73	30	165603	13882	32334011
Mydriasis	15.02	10.73	7	165626	6439	32341454
Puncture site haematoma	15.01	10.73	10	165623	166	32347727
Diabetic neuropathy	14.98	10.73	51	165582	4109	32343784
Lymphopenia	14.98	10.73	32	165601	14424	32333469
Posterior reversible encephalopathy syndrome	14.95	10.73	16	165617	9560	32338333
Renal tubular disorder	14.94	10.73	4	165629	5198	32342695
Burning feet syndrome	14.93	10.73	8	165625	87	32347806
Sperm concentration zero	14.92	10.73	4	165629	3	32347890
Macular degeneration	14.90	10.73	33	165600	2064	32345829
Angle closure glaucoma	14.86	10.73	19	165614	753	32347140
Hepatic enzyme increased	14.84	10.73	119	165514	36918	32310975
Bovine tuberculosis	14.83	10.73	9	165624	126	32347767
Breast disorder male	14.82	10.73	5	165628	14	32347879
Right ventricular hypertrophy	14.76	10.73	21	165612	923	32346970
Gallbladder hypofunction	14.57	10.73	5	165628	15	32347878
Neurogenic bladder	14.57	10.73	29	165604	1683	32346210
Urethral pain	14.50	10.73	6	165627	34	32347859
Dysphagia	14.48	10.73	413	165220	61063	32286830
Metabolic acidosis	14.43	10.73	135	165498	40564	32307329
Arteriovenous fistula	14.40	10.73	18	165615	697	32347196
Residual urine volume increased	14.39	10.73	4	165629	4	32347889
Colitis ulcerative	14.35	10.73	42	165591	17009	32330884
Dysstasia	14.33	10.73	104	165529	11382	32336511
Inflammation	14.32	10.73	70	165563	24423	32323470
Faecaloma	14.32	10.73	55	165578	4701	32343192
Diabetes mellitus	14.29	10.73	154	165479	45019	32302874
Hypertriglyceridaemia	14.26	10.73	14	165619	8705	32339188
Benign gastrointestinal neoplasm	14.24	10.73	9	165624	136	32347757
Klebsiella infection	14.13	10.73	12	165621	8000	32339893
Hepatic function abnormal	14.13	10.73	153	165480	44687	32303206
Hepatic steatosis	14.12	10.73	39	165594	16094	32331799
Acidosis	13.94	10.73	21	165612	10825	32337068
Myxoedema coma	13.92	10.73	12	165621	298	32347595
Hyponatraemic syndrome	13.91	10.73	11	165622	241	32347652
Pulmonary function test abnormal	13.90	10.73	32	165601	2054	32345839
Hepatocellular injury	13.87	10.73	74	165559	25244	32322649
Loss of bladder sensation	13.83	10.73	7	165626	67	32347826
Respiratory distress	13.78	10.73	114	165519	35132	32312761
Cardiotoxicity	13.78	10.73	4	165629	4928	32342965
Pain in extremity	13.75	10.73	739	164894	118162	32229731
Calculus bladder	13.74	10.73	20	165613	898	32346995
Chronic obstructive pulmonary disease	13.63	10.73	335	165298	48418	32299475
Blood pressure systolic	13.50	10.73	4	165629	6	32347887
Metastases to neck	13.50	10.73	4	165629	6	32347887
Suprapubic pain	13.49	10.73	13	165620	374	32347519
Breast enlargement	13.47	10.73	14	165619	442	32347451
Arteriosclerotic gangrene	13.40	10.73	7	165626	72	32347821
Testicular pain	13.34	10.73	39	165594	2897	32344996
Ventricular enlargement	13.24	10.73	14	165619	451	32347442
Sepsis	13.16	10.73	668	164965	158166	32189727
Muscle spasms	13.14	10.73	460	165173	69958	32277935
Psoriasis	13.12	10.73	161	165472	45962	32301931
Prostate cancer metastatic	13.03	10.73	62	165571	5823	32342070
Venoocclusive liver disease	13.03	10.73	11	165622	7354	32340539
Hyponatraemia	12.99	10.73	483	165150	74030	32273863
Hepatic cytolysis	12.92	10.73	14	165619	8319	32339574
Subdural hygroma	12.90	10.73	12	165621	330	32347563
Vertigo CNS origin	12.85	10.73	3	165630	0	32347893
Prostatic acid phosphatase increased	12.85	10.73	3	165630	0	32347893
Iris injury	12.85	10.73	3	165630	0	32347893
Pupillary block	12.85	10.73	3	165630	0	32347893
Blood creatine phosphokinase increased	12.84	10.73	159	165474	45317	32302576
Bronchial secretion retention	12.83	10.73	21	165612	1045	32346848
Flatulence	12.83	10.73	153	165480	19202	32328691
Paraplegia	12.81	10.73	37	165596	2729	32345164
Cystitis haemorrhagic	12.80	10.73	5	165628	5109	32342784
Colitis	12.74	10.73	111	165522	33840	32314053
Osteonecrosis	12.54	10.73	43	165590	16579	32331314
Disease recurrence	12.50	10.73	41	165592	16023	32331870
Injection site pain	12.44	10.73	108	165525	32950	32314943
Spinal fracture	12.32	10.73	70	165563	7046	32340847
Drug withdrawal syndrome	12.31	10.73	57	165576	20174	32327719
Choroidal detachment	12.29	10.73	12	165621	351	32347542
Pulmonary tuberculosis	12.29	10.73	5	165628	4984	32342909
Dental restoration failure	12.28	10.73	5	165628	27	32347866
Ventricular fibrillation	12.25	10.73	46	165587	17264	32330629
Invasive ductal breast carcinoma	12.18	10.73	4	165629	10	32347883
Multiple system atrophy	12.09	10.73	10	165623	234	32347659
Oesophageal rupture	12.09	10.73	13	165620	427	32347466
Femoral artery aneurysm	12.08	10.73	9	165624	180	32347713
Systemic infection	11.90	10.73	31	165602	2152	32345741
Frostbite	11.89	10.73	6	165627	57	32347836
Stoma site oedema	11.85	10.73	5	165628	30	32347863
BK virus infection	11.85	10.73	5	165628	4876	32343017
Blood glucose fluctuation	11.78	10.73	46	165587	3963	32343930
Bladder tamponade	11.74	10.73	14	165619	516	32347377
Bronchial wall thickening	11.60	10.73	19	165614	946	32346947
Stomatitis	11.60	10.73	140	165493	40089	32307804
Pharyngeal cancer	11.58	10.73	5	165628	32	32347861
Bladder obstruction	11.53	10.73	15	165618	605	32347288
Hepatic necrosis	11.52	10.73	3	165630	3972	32343921
Respiratory depression	11.51	10.73	32	165601	13179	32334714
Urogenital disorder	11.46	10.73	6	165627	62	32347831
Radiation inflammation	11.46	10.73	8	165625	144	32347749
Taste disorder	11.45	10.73	51	165582	4660	32343233
Accidental exposure to product	11.44	10.73	25	165608	11177	32336716
Executive dysfunction	11.31	10.73	9	165624	199	32347694
Bedridden	11.31	10.73	44	165589	3784	32344109
Hepatocellular carcinoma	11.26	10.73	22	165611	10248	32337645
Haemorrhage urinary tract	11.25	10.73	26	165607	1673	32346220
Lower respiratory tract infection	11.24	10.73	95	165538	29148	32318745
Inappropriate antidiuretic hormone secretion	11.14	10.73	102	165531	11961	32335932
Tendon discomfort	11.12	10.73	10	165623	263	32347630
Diarrhoea	11.10	10.73	2064	163569	362738	31985155
Drug eruption	11.08	10.73	55	165578	19111	32328782
Wrong schedule	11.00	10.73	8	165625	154	32347739
Hypoxia	10.98	10.73	193	165440	51939	32295954
Lichen sclerosus	10.98	10.73	4	165629	15	32347878
Dyspnoea exertional	10.98	10.73	268	165365	38693	32309200
Serotonin syndrome	10.97	10.73	55	165578	19062	32328831
Wound haematoma	10.91	10.73	6	165627	69	32347824
Iris adhesions	10.91	10.73	9	165624	210	32347683
Blood pressure decreased	10.90	10.73	339	165294	50741	32297152
International normalised ratio increased	10.88	10.73	327	165306	48708	32299185
Anorectal operation	10.79	10.73	3	165630	3	32347890
Inadequate osteointegration	10.78	10.73	4	165629	16	32347877
Tenosynovitis	10.78	10.73	3	165630	3800	32344093
Aplastic anaemia	10.77	10.73	13	165620	7360	32340533
Visual impairment	10.75	10.73	231	165402	32657	32315236

Pharmacologic Action:

Source	Code	Description
ATC	G04CA02	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA52	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA53	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA54	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
FDA EPC	N0000175553	alpha-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
CHEBI has role	CHEBI:35610	cytostatic
CHEBI has role	CHEBI:37890	alpha-adrenoceptor antagonists

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Benign prostatic hyperplasia	indication	266569009
Priapism	contraindication	6273006	DOID:9286
Orthostatic hypotension	contraindication	28651003
Oligozoospermia	contraindication	88311004
Cataract surgery	contraindication	110473004
Disease of liver	contraindication	235856003	DOID:409
Syncope	contraindication	271594007
Pregnancy, function	contraindication	289908002
Dizziness	contraindication	404640003
Breastfeeding (mother)	contraindication	413712001
Intraoperative floppy iris syndrome	contraindication	418801006
High-Grade Prostate Cancer	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.71	acidic
pKa2	8.16	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	Ki	7.89	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	Ki	7.87	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	Ki	9.10	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	Ki	7.08	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	Ki	10.54	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	Ki	9.55	CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	Ki	8.10	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	Ki	10.24	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	Ki	9.21	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT	Ki	10.52	CHEMBL
Alpha-2B adrenergic receptor	GPCR		ADA2B_RAT	Ki	8.17	CHEMBL
Alpha-1D adrenergic receptor	GPCR		ADA1D_RAT	Ki	10.15	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN	Ki	9.90	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_MESAU	Ki	9.70	CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT	Ki	6.03	CHEMBL

External reference:

ID	Source
4024076	VUID
N0000022081	NUI
D01024	KEGG_DRUG
106463-17-6	SECONDARY_CAS_RN
4021051	VANDF
4024076	VANDF
C0257343	UMLSCUI
CHEBI:9398	CHEBI
CHEMBL836	ChEMBL_ID
CHEMBL1200914	ChEMBL_ID
D000077409	MESH_DESCRIPTOR_UI
DB00706	DRUGBANK_ID
129211	PUBCHEM_CID
488	IUPHAR_LIGAND_ID
6750	INN_ID
G3P28OML5I	UNII
236495	RXNORM
171693	MMSL
20642	MMSL
5541	MMSL
d04121	MMSL
006115	NDDF
006116	NDDF
108559004	SNOMEDCT_US
108560009	SNOMEDCT_US
372509005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FLOMAX	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5837	CAPSULE	0.40 mg	ORAL	NDA	30 sections
JALYN	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0809	CAPSULE	0.40 mg	ORAL	NDA	29 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2996	CAPSULE	0.40 mg	ORAL	ANDA	19 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7995	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8055	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2076	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6401	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Dutasteride and Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	10370-280	CAPSULE	0.40 mg	ORAL	ANDA	28 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-280	CAPSULE	0.40 mg	ORAL	ANDA	18 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-550	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-298	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
FLOMAX	HUMAN PRESCRIPTION DRUG LABEL	1	16590-489	CAPSULE	0.40 mg	ORAL	NDA	28 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	16714-713	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-839	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	33342-159	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42254-012	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-264	CAPSULE	0.40 mg	ORAL	ANDA	19 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-725	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-947	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-013	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	43353-019	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-663	CAPSULE	0.40 mg	ORAL	ANDA	19 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50090-1846	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50090-3646	CAPSULE	0.40 mg	ORAL	ANDA	29 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50090-4906	CAPSULE	0.40 mg	ORAL	ANDA	29 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50090-5553	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-740	CAPSULE	0.40 mg	ORAL	ANDA	30 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50436-0598	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51655-677	CAPSULE	0.40 mg	ORAL	ANDA	14 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52959-034	CAPSULE	0.40 mg	ORAL	ANDA	17 sections